As part of our integrated Pharmaceutical Development & Manufacturing framework and nested within Drug Substance Development, we provide end-to-end peptide therapeutics development focused on robust, phase-appropriate chemistry, analytics, and preformulation science. Our programs align sequence design, process feasibility, and stability engineering to deliver well-characterized peptide APIs and advanced peptide conjugates.
Overview of Peptide Therapeutics
Peptide therapeutics are a class of drugs composed of short chains of amino acids that bridge the gap between small-molecule drugs and large biologics, offering high specificity, strong biological activity, and relatively low toxicity. They can mimic natural peptides involved in physiological processes, enabling precise modulation of targets such as receptors, enzymes, and protein–protein interactions, and are widely used in areas including metabolic diseases, cancer, infectious diseases, and endocrine disorders. Nowadays, advances in solid-phase synthesis, orthogonal protection strategies, and high-resolution analytics have transformed peptide therapeutics development workflows, allowing rapid iteration from sequence hypothesis to manufacturability assessment. Key technical priorities include mitigation of sequence-dependent liabilities (e.g., aggregation, oxidation, deamidation, and epimerization), control of isomeric and truncation impurities, counterion and salt selection, and stabilization via cyclization or targeted modifications. When required, peptides can be conjugated to small-molecule payloads or oligonucleotides using linkers with defined cleavage mechanisms to modulate disposition, distribution, and durability.
Our Services
We deliver a coherent suite of peptide development services that convert promising sequences into phase-appropriate, well-controlled drug substances. Programs integrate synthetic route design, orthogonal impurity control, stability-indicating method development, and preformulation study. We summarize three complementary offerings that collectively support linear and complex peptides as well as peptide–payload conjugates.
We provide comprehensive peptide therapeutics development services that integrate advanced peptide synthesis, state-of-the-art modification chemistry, and innovative bioconjugation technologies with rigorous analytical characterization and stability science. Our capabilities span the full spectrum of peptide modalities, from simple linear APIs to structurally complex macrocyclic peptides, as well as PDC/POC constructs. Supported by experienced multidisciplinary teams, we design robust synthetic routes, establish well-defined control strategies, and deliver high-quality, development-grade materials tailored to each stage of clinical development. Contact us to initiate a focused, phase-appropriate program that accelerates progress from early research through clinical advancement.
Frequently Asked Questions
Q1: How do you decide between pure SPPS, fragment condensation, or hybrid routes?
Route selection is driven by sequence length, hydrophobicity, motif complexity, and epimerization risk. We model stepwise yields, predict hot spots, and evaluate convergent fragments to reduce cycle count. Hybrid strategies are favored when difficult segments benefit from solution-phase couplings or when macrocyclization efficiency improves off-resin.
Q2: What controls are used to manage stereochemical integrity and epimerization?
We employ minimized base exposure, rapid couplings, and epimerization-suppressing reagents. Risk residues (e.g., Cys, His, Asp, Ser, Thr) receive tailored protocols. Chiral assays, mapping digests, and orthogonal chromatographic methods confirm L-configurations and quantify any D-isomer content within phase-appropriate limits.
Q3: What analytical framework supports complex macrocycles and conjugates?
We combine high-resolution LC-MS (intact and fragment), UPLC with multiple detectors, CE for charge variants, and SEC for aggregation. For conjugates, dual-channel quantitation tracks both peptide and payload; deconvolution confirms exact mass, while stress panels challenge linker robustness and define degradation pathways.
Our products and services are for research use only.
